Ex Parte Akashe et al - Page 7



          Appeal No. 2005-2629                                                        
          Application No. 10/377,474                                                  

               Regarding the § 103 rejection of claims 19 and 20 over the             
          combined teachings of Cope, Blauel and Chang, we agree with the             
          examiner that Blauel evidences the obviousness of using soy                 
          protein in the claimed range of about 0.5 to about 5% of the                
          emulsion.  Blauel discloses concentrations of soy protein within            
          the claimed range which stabilize an aqueous emulsion comprising            
          nutritionally desirable omega-3 fatty acids.  Accordingly, we               
          concur with the examiner that one of ordinary skill in the art              
          would have found it obvious to use the claimed amounts of soy               
          protein in the aqueous emulsions of Cope for the purpose of                 
          stabilizing the emulsions.  It is not necessary for a finding of            
          obviousness that the prior art also teach the effect of reducing            
          the rate of oxidation of the omega-3 polyunsaturated lipids.                
          Appellants have not established that the prior art use of soy               
          protein to stabilize the emulsion would not also bring about the            
          anti-oxidant effect.  Appellants' argument that Blauel does not             
          teach that the soy protein isolate would be effective as an anti-           
          oxidant does not address the thrust of the examiner's rejection.            
               As a final point, we note that appellants base no argument             
          upon objective evidence of nonobviousness, such as unexpected               



                                         -7-                                          



Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007